Literature DB >> 15308354

Potential conflicts of interest in vaccine economics research: a commentary with a case study of pneumococcal conjugate vaccination.

Philippe Beutels1.   

Abstract

The main potential areas of bias in economic evaluation (EE) in health care can be categorised as follows: (1) choosing the study question and design, (2) estimating clinical effectiveness; (3) choosing cost data sources, and (4) reporting and dissemination of results. Each of these is discussed while focusing on vaccines. In addition a case study is presented on two contemporary economic evaluations of pneumococcal conjugate vaccination for Canada. Though they are quite similar in design and methods, their results are not quite so. This paper explores the differences between them in relation to the four areas of bias. Finally, remedies to avoid bias in research and publications are proposed and discussed.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15308354     DOI: 10.1016/j.vaccine.2004.03.001

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  9 in total

Review 1.  Economic Evidence of Pneumococcal Vaccination in Older Adults: Uncertain Modelling or Competitive Tendering?

Authors:  Livio Garattini; Anna Padula; Milene Rangel Da Costa
Journal:  Pharmacoeconomics       Date:  2016-03       Impact factor: 4.981

Review 2.  Reviewing the cost effectiveness of rotavirus vaccination: the importance of uncertainty in the choice of data sources.

Authors:  Joke Bilcke; Philippe Beutels
Journal:  Pharmacoeconomics       Date:  2009       Impact factor: 4.981

3.  Incidence of pneumonia is not reduced by pneumococcal conjugate vaccine.

Authors:  Sona Chowdhary; Jacob Puliyel
Journal:  Bull World Health Organ       Date:  2008-10       Impact factor: 9.408

4.  Industry involvement and baseline assumptions of cost-effectiveness analyses: diagnostic accuracy of the Papanicolaou test.

Authors:  Nikolaos P Polyzos; Antonis Valachis; Davide Mauri; John P A Ioannidis
Journal:  CMAJ       Date:  2011-03-14       Impact factor: 8.262

Review 5.  Cost effectiveness of the new pneumococcal vaccines: a systematic review of European studies.

Authors:  Katelijne van de Vooren; Silvy Duranti; Alessandro Curto; Livio Garattini
Journal:  Pharmacoeconomics       Date:  2014-01       Impact factor: 4.981

6.  The burden of pneumococcal disease in the Canadian population before routine use of the seven-valent pneumococcal conjugate vaccine.

Authors:  Adrienne Morrow; Philippe De Wals; Geneviève Petit; Maryse Guay; Lonny James Erickson
Journal:  Can J Infect Dis Med Microbiol       Date:  2007-03       Impact factor: 2.471

7.  Pneumococcal conjugate vaccination in Canadian infants and children younger than five years of age: Recommendations and expected benefits.

Authors:  Carol A McClure; Michael W Ford; Jeff B Wilson; Jeff J Aramini
Journal:  Can J Infect Dis Med Microbiol       Date:  2006-01       Impact factor: 2.471

8.  Burden of disease and economic evaluation of healthcare interventions: are we investigating what really matters?

Authors:  Ferrán Catalá-López; Anna García-Altés; Elena Alvarez-Martín; Ricard Gènova-Maleras; Consuelo Morant-Ginestar; Antoni Parada
Journal:  BMC Health Serv Res       Date:  2011-04-13       Impact factor: 2.655

Review 9.  When are statins cost-effective in cardiovascular prevention? A systematic review of sponsorship bias and conclusions in economic evaluations of statins.

Authors:  Ferrán Catalá-López; Gabriel Sanfélix-Gimeno; Manuel Ridao; Salvador Peiró
Journal:  PLoS One       Date:  2013-07-08       Impact factor: 3.240

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.